Journal
CURRENT SIGNAL TRANSDUCTION THERAPY
Volume 6, Issue 3, Pages 428-440Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157436211797483930
Keywords
TLR; signaling pathways; therapy
Categories
Funding
- NIH [HL083327, HL067307, HL08675]
- Medical College of Georgia
Ask authors/readers for more resources
This review summarizes the key role of Toll-Like Receptor (TLRs) molecules for igniting the immune system. Activated by a broad spectrum of pathogens, cytokines or other specific molecules, TLRs trigger innate immune responses. Published data demonstrate that the targeting and suppression of TLRs and TLR-related proteins with particular inhibitors may provide pivotal treatments for patients with cancer, asthma, sepsis, Crohn's disease and thrombosis. Many drugs that target cytokines act in the late phases of the activated pathways, after the final peptides, proteins or glycoproteins are formed in the cell environment. TLR activity occurs in the early activation of cellular pathways; consequently inhibiting them might be most beneficial in the treatment of human diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available